PT - JOURNAL ARTICLE AU - Lela Kardava AU - Nicholas Rachmaninoff AU - William W. Lau AU - Clarisa M. Buckner AU - Krittin Trihemasava AU - Felipe Lopes de Assis AU - Wei Wang AU - Xiaozhen Zhang AU - Yimeng Wang AU - Chi-I Chiang AU - Sandeep Narpala AU - Robert Reger AU - Genevieve E. McCormack AU - Catherine A. Seamon AU - Richard W. Childs AU - Anthony F. Suffredini AU - Jeffrey R. Strich AU - Daniel S. Chertow AU - Richard T. Davey AU - Michael C. Sneller AU - Sarah O’Connell AU - Yuxing Li AU - Adrian McDermott AU - Tae-Wook Chun AU - Anthony S. Fauci AU - John S. Tsang AU - Susan Moir TI - Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine AID - 10.1101/2021.07.06.21259528 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.06.21259528 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259528.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259528.full AB - SARS-CoV-2 mRNA vaccines are highly effective, although weak antibody responses are seen in some individuals with correlates of immunity that remain poorly understood. Here we longitudinally dissected antibody, plasmablast, and memory B cell (MBC) responses to the two-dose Moderna mRNA vaccine in SARS-CoV-2-uninfected adults. Robust, coordinated IgA and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses, but earlier and more intensely after dose two. Distinct antigen-specific MBC populations also emerged post-vaccination with varying kinetics. We identified antigen non-specific pre-vaccination MBC and post-vaccination plasmablasts after dose one and their spike-specific counterparts early after dose two that correlated with subsequent antibody levels. These baseline and response signatures can thus provide early indicators of serological efficacy and explain response variability in the population.Competing Interest StatementYM is founder/CEO of ReVacc, Inc.Clinical TrialNCT00001281, NCT04411147, NCT04280705, and NCT04579393Funding StatementThis work was funded by the Intramural Research Program of the NIAID of the NIH. YL was supported by NIH extramural grant R01AI102766 and by the University of Maryland Strategic Partnership (MPower).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research phlebotomy was performed at the NIH Clinical Research Center in Bethesda, MD under protocols approved by the NIH Institutional Review Board, ClinicalTrials.gov identifiers: NCT00001281, NCT04411147, NCT04280705, and NCT04579393. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or supplementary materials.